US Patent Issued to Mitsubishi Tanabe Pharma on June 24 for "Crosslinked artificial nucleic acid ALNA" (Japanese Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,265, issued on June 24, was assigned to Mitsubishi Tanabe Pharma Corp. (Osaka, Japan).

"Crosslinked artificial nucleic acid ALNA" was invented by Hiroaki Sawamoto (Osaka, Japan), Shinji Kumagai (Osaka, Japan), Hiroyuki Furukawa (Osaka, Japan), Tomo Araki (Osaka, Japan), Masayuki Utsugi (Osaka, Japan) and Satoshi Obika (Suita, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification)...